In postmortem Huntington's disease brains, mutant htt is present in both nuclear and cytoplasmic compartments. To dissect the impact of nuclear and extranuclear mutant htt on the initiation and progression of disease, we generated a series of transgenic mouse lines in which nuclear localization (NLS) or nuclear export sequences (NES) have been placed N-terminal to the htt exon 1 protein carrying 144 glutamines. Our data indicate that the exon 1 mutant protein is present in the nucleus as part of an oligomeric or aggregation complex. Increasing the concentration of the mutant transprotein in the nucleus is sufficient for, and dramatically accelerates the onset and progression of behavioral phenotypes. Furthermore, nuclear exon 1 mutant protein is sufficient to induce cytoplasmic neurodegeneration and transcriptional dysregulation. However, our data suggests that cytoplasmic mutant exon 1 htt, if present, contributes to disease progression.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant, neurodegenerative disorder with symptom onset usually in mid-life, comprising movement, cognitive and psychiatric impairments inexorably progressing to death within two decades (1) . The HD mutation is a CAG repeat expansion in exon 1 of the HD gene which translates into a polyglutamine (polyQ) tract in the huntingtin (htt) protein. HD neuropathology is characterized by generalized brain atrophy, selective neuronal cell death predominantly in the striatum, and intracellular polyQ aggregates (2) (3) (4) . HD is one of an increasing number of inherited neurodegenerative disorders caused by polyQ expansion, which includes spinal and bulbar muscular atrophy (SBMA), dentatorubral pallidoluysian atrophy (DRPLA) and the spinocerebellar ataxias (SCA) types 1, 2, 3, 6, 7, and 17 (5) .
In HD patients, polyQ aggregation is present mainly in the form of dystrophic neurites and neuropil aggregates (2, 4) . Although the frequency of nuclear inclusions increases in juvenile cases, extranuclear aggregation still predominates (2) . The R6/2 transgenic mouse line expresses exon 1 htt with expanded polyQ repeats, and displays a progressive neurological phenotype that recapitulates a remarkable number of features of the human disorder (6) (7) (8) . They exhibit an early the nucleus and cytoplasm (NES144). The mutant transprotein was only present in the nucleus as part of an aggregation complex. We found that targeting the mutant transprotein to the nucleus dramatically accelerated the onset and progression of behavioral phenotypes for any comparable RNA expression level. Obvious cytoplasmic neurodegeneration in the form of degenerate organelles and dystrophic neurites was present in both sets of lines and can therefore be caused by mutant htt in the nucleus. Comparison of well-matched NLS144 and NES144 lines for the onset and progression of behavioural phenotypes, cytoplasmic degeneration and microarray gene expression profiles indicated that extranuclear mutant htt also contributes to disease pathogenesis.
RESULTS

Generation of transgenic mouse lines
To dissect the contribution of a nuclear or extranuclear localization of expanded polyQ we generated constructs that fused previously well-characterized nuclear localization or nuclear export signals (NLS or NES) with the exon 1 htt protein (Fig. 1A) . Like the R6 lines, the transgene was under the control of human HD promoter sequences (6) . Localization signals were placed at the N-terminus of the exon 1 protein downstream of a FLAG tag. The sequence 7 lung, skeletal muscle, spleen, gonads) and RT-PCR confirmed that the transgene was ubiquitously expressed in all cases (data not shown). Furthermore, in situ hybridization for transgenic mRNA (Fig. 2B ) revealed no gross differences in the pattern of expression within the brain for all of the lines (Fig. 2B,C) .
The NLS signal results in the accumulation of aggregated protein in the nucleus
To assess subcellular localization signal effects at the protein level, nuclear and cytoplasmic fractions were prepared from whole brain homogenates and used for western blotting ( Fig. 2D-G ). Blots were routinely reprobed with antibodies to proteins with uniquely nuclear or cytoplasmic distributions to confirm that the fractions were cleanly separated. There is an inherent difficulty of ensuring that high molecular weight cytoplasmic aggregates do not sediment with the nuclear fraction. We therefore complemented the western analysis by chronicling the regional and subcellular distribution of polyQ aggregate neuropathology by immunohistochemistry ( Fig. 3 ) focusing on striatum, cerebral cortex, hippocampus and cerebellum. Brains sections were immunostained with EM48 and S830 (which detect exon 1 htt), ubiquitin and FLAG antibodies.
A specific band corresponding to soluble exon 1 protein was never detected in either nuclear or cytoplasmic fractions prepared from NLS144 lines 25, 46 or 52 irrespective of age or disease state (Fig. 2D) . Inspection of the stacking gel suggested that aggregated transprotein had been retained in nuclear but not cytoplasmic fractions (Fig. 2E ). The amount of aggregation seen in the stacking gel does not correlate with the amount of protein in the nucleus; rather it represents protein accumulation over time. Immunohistochemistry confirmed that the NLS signal had restricted the mutant transprotein to the nucleus (Fig. 3A,D ,G,J), where the nuclear pathology first appeared as a granular nuclear stain which progressed to one that included small puncta and finally to a pronounced nuclear inclusion. As soluble bands in the nuclear fraction were never detected for the NLS144 lines, it would appear that all these forms of the nuclear transprotein represent an aggregated state. Relative transgene expression levels (by RQ-PCR) in the NLS144 lines correlated with the order in which the nuclear pathology appeared e.g. polyQ coalescence occurred earlier and progressed faster in line 25 than line 46.
Analysis of the NLS20 line 50 revealed soluble transprotein in the cytoplasmic fraction only (Fig. 2G, upper arrow) . This can be compared to the smaller cytoplasmic protein seen in Hdex6 and Hdex27 lines expressing exon 1 htt protein with 20Q, without additional FLAG tag or localization sequences (Fig. 2G , lower arrow) (6,12). There was no aggregated transprotein in the stacking gels in either nuclear or cytoplasmic fractions at any time point (up to 16 months).
Similarly, immunohistochemistry on NLS20 line 50 brains did not reveal an aggregate pathology with any antibodies at any time point up to 15 months (Fig. 3F,L) .
The NES signal failed to exclude the mutant transprotein from the nucleus 9 pathologies (Fig. 3B,C ,E,H,I,K). The same range and progression of nuclear pathologies was present in the NES144 lines as the NLS144 lines.
Immunostaining of NES144 sections with a FLAG antibody preferentially detected extranuclear aggregates, with extremely weak nuclear aggregate staining when compared to EM48 or S830 labeling on adjacent sections (Fig. 3N ,O,Q,P). This is consistent with a model in which the mutant transprotein is retained in the nucleus because formation of aggregation complexes masks the N-terminus encoding the FLAG tag and localization sequences. It also suggests that nuclear and extranuclear aggregates may have different morphologies.
Targeting polyQ to the nucleus accelerates the onset of behavioral phenotypes. RotaRod test is a sensitive and highly quantitative measure of motor impairment and a progressive RotaRod impairment was the earliest phenotype detected for all lines tested.
Unfortunately, NLS144 line 25 had an aggressive phenotype which led to its demise after the fifth generation, so insufficient mice were available for RotaRod analysis from this line. For NLS144 line 46 we compared RotaRod performance for males and females and although females tend to perform better than males, the onset and progression of impairment was equivalent in both sexes (Fig. 4A,B ). Significant RotaRod deficits (Fig. 4) We used a modified SHIRPA protocol to probe the spectrum of phenotypes displayed by each line, documenting the time at which each of these phenotypic indicators was first apparent until 12 months of age or endpoint, whichever was soonest. SHIRPA is a semi-quantitative battery of tests comprising a comprehensive set of behavioral, functional and pathological screens (22). Phenotypes identified in the transgenic lines and the times at which they first occurred are listed in Table 2 .
A progressive RotaRod impairment was the earliest phenotype detected for all lines tested. For the NES144 or NLS144 sets of lines, phenotype onset, defined by both RotaRod and SHIRPA, reflected transgene expression level ( Fig. 2A) transgene is expressed about three fold less that the NES144 line 39 transgene ( Fig. 2A ) and yet produced a dramatically more aggressive phenotype ( Table 2 ). The spectrum of phenotypes recorded was the same, but in NLS144 line 25 the onset of each was accelerated by several months. Similarly, the RNA expression level of NLS144 line 25 is around two thirds of that in the mutNLS144 line 16 control, yet the phenotypes in line 16 were detected 5-6 months after they first appeared in line 25.
The NLS144 line 25 transprotein was restricted to the nucleus and these mice developed a severe phenotype that displayed all of the behavioral deficits detected in NES144 and mutNLS144 lines. Therefore, a high concentration of mutant transprotein in the nucleus can produce a phenotype indistinguishable on a gross level from mice which also have mutant protein in the cytoplasm.
Cytoplasmic degeneration can be caused by mutant polyQ in the nucleus
We have generated and characterized transgenic mice in which the transprotein has been targeted to the nucleus (NLS144 lines 25, 46, 52) together with well-matched lines where it is present in both nuclear and extranuclear locations (NES144 lines 39, 61, 68 and mutNLS144 line 16). We conducted an ultrastructural analysis on brains from NLS144 line 46 and NES144 line 61. EM48 immunogold labeling confirmed the presence of nuclear aggregates in the cerebral cortex and striatum of NLS144 line 46 and NES144 line 61 mouse brains (Fig. 5A,B) . In addition, the NES144 line 61 transprotein formed cytoplasmic aggregates primarily found in axons and their terminals (Fig. 5C) , with occasional dendritic aggregates (data not shown). There were no obvious cytoplasmic aggregates in NLS144 line 46 mice at the age of 12 months.
Therefore EM analysis confirmed that addition of an NLS results in a nuclear accumulation of mutant htt, whereas the NES was not able to export aggregated mutant htt from the nucleus. R6/2 mice, which have an earlier onset and faster disease progression than NLS144 line the modest rate of phenotype progression in these lines. We were also unable to detect typical apoptotic neurons in NLS144 line 46 and NES144 line 61 mice, in accordance with R6/2 neuropathology. However, obvious cytoplasmic neurodegeneration was evident in the striatum and cortex in both NLS144 line 46 and NES144 line 61 at 12 and 16 months of age. These pathological changes primarily existed as clustered dark and degenerating organelles adjacent to the intact nucleus in which no nuclear DNA fragmentation or chromosomal condensation was seen (Fig. 5H) . Therefore, cytoplasmic organelle degeneration can occur in the absence of nuclear degeneration. The dark cytoplasmic bodies are similar in shape and size to lysosomes and mitochondria, suggesting that they are derived from the degeneration of these organelles. This is further inferred by the association of dark cytoplasmic bodies with large vacuoles (Fig.   5E ), which may be autophagic vacuoles derived from secondary lysosomes. In NES144 line 61, some degenerated organelles localized with htt aggregates in the same ultrathin section (Fig.   5E ,G). However, swollen axons or enlarged axons with reduced electron density or axonal contents as well as disrupted morphology were also found in NLS144 line 46 animals at 12 months ( Fig. 5I) , indicating that nuclear mutant htt alone can cause cytoplasmic degeneration.
Neither htt aggregate pathology nor cytoplasmic organelle degeneration were observed in NLS20 line 50 mice at the age of 14 months (data not shown).
Extranuclear polyQ does not influence transcriptional dysregulation
Affymetrix GeneChip arrays have been used to generate expression profiles from a wide range of polyQ disease models (25) and extensive datasets have been generated from different brain regions and tissues from the R6/2 mouse model (25-27). Accumulating evidence indicates that transcriptional dysregulation is a central and early pathogenic mechanism in HD, with several possible underlying molecular mechanisms (reviewed in (25)). It is not known whether extranuclear polyQ might influence these transcriptional changes. For example, the presence of mutant htt causes the repressor element-1 transcription factor/neuron restrictive silencing factor (REST/NRSF) complex to accumulate in the nucleus and down-regulate specific neuronal genes e.g. BDNF (28) . If this is caused by extranuclear interactions with mutant htt, then these decreases in expression might not occur if the mutant transprotein is targeted to the nucleus. To test this, we performed microarray analyses to identify gene expression changes that are present in the NES144 lines and R6/2, but not in the NLS144 lines. Cerebellum was chosen for profiling, because it is affected in juvenile HD, precision of dissection, and its known gene expression profile from previous studies with R6/2 and other HD models (26,27).
Gene expression profiles were generated from NLS144 lines 25 (12 weeks) and 46 (3. The myelin associated genes: PLP myelin proteolipid protein (PLP) and myelin associated oligodendrocyte basic protein (MOBP) appeared to be decreased in the NES144 lines 39 and 61 but not in the NLS line 46. We found the absence of an effect on MOBP expression interesting as a statistically significant decrease in the expression of these genes had previously been detected in the cerebella of R6/2, N171-82Q and DRPLA mice (27). We performed western blots to determine whether specific decreases in mRNA levels had translated to deficits in the protein levels. We found a significant decrease in MOBP cerebellar protein levels in R6/2 (14 weeks) and NES144 line 39 (8 months) but not in NLS144 line 46 at 8 or 17 months of age ( Fig.   6b ). Therefore, the decrease in MOBP levels corresponds to the mRNA deficits identified by microarray. MOBP protein levels were also marginally decreased (>5%) in the NLS144 line 25 as compared to wild type. However, this change most likely only reached significance because the error bars were so tight and analysis of a larger sample would be required to confirm whether there is any change in MOBP levels in NLS144 lines 25. Further analysis is also required to determine whether the decrease in MOBP in the NES144 and R6/2 lines would be sufficient to contribute to pathogenesis.
DISCUSSION
In order to further unravel the importance of the subcellular location of the expanded polyQ in Huntington's disease, we generated 30 transgenic founders expressing exon 1 htt with 20 or 144Q fused to a FLAG tag and either an NLS or NES signal. Transgenic mouse lines were established from these founders and lines were selected for analysis on the basis of transgene mRNA expression levels.
Localization signals did not always result in the intended nuclear or cytoplasmic localization
We were unable to establish a line in which non-pathogenic exon 1 htt was restricted to the nucleus. The NLS20 transprotein was only detected in cytoplasmic fractions on western blots. A potential mechanism for this comes from our recent demonstration that exon 1 htt is exported from the nucleus through its interaction with the nuclear pore protein, Tpr, which overrides the effect of a functional NLS sequence (29) . The Tpr binding sequence is located within the first 17 amino acids of exon 1. We hypothesize that the NLS directs the nonpathogenic exon 1 protein to the nucleus only for it to be expelled through interactions with the Tpr protein.
In the case of transgenic proteins with expanded repeats, both NES144 and NLS144 were observed in the nucleus. The NLS signal most likely successfully directs and concentrates the NLS144 protein in the nucleus. A proportion of the NES144 or mutNLS144 proteins might enter the nucleus by passive diffusion, or through interactions with other proteins. We propose that the 144Q exon 1 proteins are then retained in the nucleus because the initiation of the misfolding and aggregation processes masks the Tpr binding sequence (and the NES signal if applicable), thus preventing the nuclear export of the 144Q protein. Although the Tpr and NES sequences could also become inaccessible through interactions with other proteins, our inability to detect a soluble transprotein in the nucleus in R6/2 or any of the NLS144, NES144 or mutNLS144 lines suggests that it is more likely due to detergent insoluble self-association. In addition, the FLAG antibody was able to detect extranuclear but not nuclear aggregates, which is supportive of nuclear aggregate structure in which the N-terminus is involved in interactions that render it inaccessible, and also hints at different aggregate morphologies in the two compartments.
Thus we were unable to generate any lines in which a pathogenic exon 1 protein was restricted to the cytoplasm. However, we were able to compare two well-matched series of mice, one in which the mutant transprotein was restricted to the nucleus and the second in which it was present in both the nucleus and the cytoplasm. This allowed us to assess the effects of an exclusively nuclear transgene localization when compared to appropriate controls.
Directing mutant exon 1 htt to the nucleus accelerates the onset of a neurological phenotype
Our data clearly demonstrate that targeting N-terminal mutant htt to the nucleus accelerates the onset of the phenotype. The RNA expression level of NLS144 line 25 is around two thirds of that in mutNLS144 line 16, yet the phenotypes in line 16 were detected 5-6 months after they first appeared in line 25. This contradicts a recent publication describing transgenic mice in which the N-terminal 171 amino acids of mutant htt with 82Q was directed to the nucleus by the addition of an NLS signal (18) . These mice were reported to develop the same phenotype as the original N17182Q mice but with a delayed phenotype onset. The reason for this discrepancy is most likely because the authors did not generate control lines containing mutant versions of the additional targeting sequence, and the original N17182Q mice do not provide good controls. For example, the transprotein in mutNLS144 line 16 contains exon 1 (as in line R6/2) but with additional FLAG tag and mutant NLS sequences. The RNA expression of the transgene in line 16 is more than two fold that in R6/2, but the onset of RotaRod impairment is at 6 months in line 16 as opposed to 1.5 months in R6/2. The additional residues have no effect on transprotein location but dramatically delay phenotype onset and progression and therefore R6/2 could not be used as the control in these experiments. Lines carrying mutant versions of the localization signals must be used when inferring the effects of targeting sequences on phenotype onset and progression. Consistent with this, the addition of epitope tags to polyQ sequences in Drosophila models has been shown to considerably attenuate disease severity (30) .
The NLS144 transprotein in line 25 was restricted to the nucleus and these mice developed a severe phenotype that displayed all of the behavioral deficits detected in the NES144 and mutNLS144 lines. Therefore, a high concentration of mutant transprotein in the nucleus can produce a phenotype that is indistinguishable on a gross level from that in mice that also have mutant protein in the cytoplasm. This is consistent with the NLS-N17182Q mice which had a phenotype that closely resembled the original N17182Q mice suggesting that disruption of nuclear processes might be a predominant mechanism of toxicity (18) .
Does cytoplasmic mutant polyQ contribute to the neurological phenotype?
NES144 line 39 line had an onset of RotaRod impairment at 4 months of age and developed an overt neurological disorder progressing to an endpoint at 10.5 months. Similarly, although NES144 line 61 had a later onset of RotaRod impairment (7 months) and slower disease progression, it too had displayed many SHIRPA phenotypes by 12 months of age. In contrast although impairment in RotaRod performance could be detected as early as 3 months of age in NLS144 line 46, these mice had not developed any obvious neurological symptoms by 12 months and endpoint had not been reached by 20 months.
An ultrastructural analysis of the cerebral cortex and striatum from NES144 line 61 and NLS144 line 46 brains from mice aged one year showed comparable cytoplasmic degeneration manifesting as dystrophic neurites, axonal swelling and organelle degeneration. This surprising finding indicated that nuclear mutant htt alone can cause cytoplasmic degeneration. However, the difference in phenotype presentation between the NES144 lines 39 and 61 and the NLS144 line 46 indicates that this cytoplasmic degeneration is not responsible for the neurological phenotypes detected by SHIRPA.
We found that microarray expression profiles of cerebellar mRNA from NES144 lines 39 and 61, and NLS line 46 as compared to wild type controls were essentially identical to each other and to previously published profiles of R6/2 mice (26,27). This was even the case for expression profiles from NES144 line 39 and NLS144 line 46 at 10 months of age, a time at which line 39 is close to end point and line 46 does not display any overt phenotypes ( Table 2 ).
As the mechanisms by which mutant htt is proposed to cause transcriptional dysregulation are global e.g. chromatin remodeling, impairment of TBP function (25), we would expect that the expression profiles of other brain regions from these lines would also be very similar to each other. It would seem that nuclear transprotein is sufficient for transcriptional dysregulation, which overall does not account for the overt neurological phenotypes identified by the SHIRPA analysis (Table 2 ). However, in the cerebellum, there were two genes that were downregulated in NES144 line 39 as compared to NLS line 46, which encode components of CNS myelin and may contribute to the NES144 line 39 and 61 phenotypes e.g. tremors, and therefore merit further investigation. The decreases in CNS myelin components would be consistent with recent reports of decreased white matter volumes throughout the brain in early stage HD (31, 32) .
In order to be able to definitively assign the neurological phenotypes observed in NES144 lines 39 and 61 that were not present in NLS144 line 46 as consequences of cytoplasmic mutant polyQ, it is necessary to compare the levels of the mutant protein in the nucleus.
Unfortunately, this is impossible to quantify as the soluble transprotein is never detected in the nucleus in any of these lines. However, non-quantitative immunohistochemistry consistently showed comparable levels of aggregated protein in the neuronal nuclei in brain sections from these two mouse lines, suggesting that is no dramatic discrepancy between the levels of nuclear protein. degeneration. This suggests that the extranuclear mutant polyQ may be contributing to the neurological phenotype in these lines. Specific mechanisms by which this might be occurring have been identified and include, among others, disruption of the microtubule transport pathways (33,34), the inhibition of synaptic function and glutamate release (35,36), mitochondrial calcium defects (37) and excititoxicty and defects in calcium signaling (38). This series of transgenic mouse lines will provide an invaluable resource to further unravel the mechanisms through which nuclear and extranuclear exon 1 mutant htt contributes to HD pathogenesis. However, in order to clearly define the role of extranuclear polyQ, it will be essential to generate lines of mice in which a pathogenic exon 1 protein is restricted to the cytoplasm. Therefore, our data underscore the critical role of the nucleus in the pathogenesis of HD but indicate that extranuclear polyQ might also contribute to this process.
CONCLUSION
MATERIALS AND METHODS
Transgene construction
Plasmids p4G6E4.0 and pSKE4.0 contain a 4kb EcoRI fragment with 3.6kb of the HD promoter, exon 1 with 18 and 142 CAG repeats respectively and 0.3kb of intron 1. The plasmids were linearized with XcmI, dephosphorylated and ligated with the FLAG tag (annealed phosphorylated oligonucleotides 40142 and 40143) ( Table 3 ). This placed a methionine codon before the FLAG tag and mutated the methionine at the beginning of exon 1 to an isoleucine.
The FLAG tag containing plasmids were linearized with KpnI, dephosphorylated and ligated with annealed phosphorylated oligonucleotides containing the sequence for either a functional NLS (40191 and 40192), a mutant NLS (40193 and 40194), a functional NES (40169 and 40170) or a mutant NES (40171 and 40172). Resultant plasmids were sequenced prior to SacI and EcoRI digestion to yield a microinjection fragment. Sequencing was performed using an ABI377 automated DNA sequencer using a rhodamine dye terminator ready reaction mix (Perkin Elmer). Sequencing primers were: 40031, 40155, 40080, 40085, 33934 and 40036 (Fig.   1a ).
Generation and maintenance of transgenic mice and genotyping
The microinjection fragments of 1.6/1.9 kb (with 18/142 CAG repeats), were purified Transgenic status of the founders and the first two generations of established lines was confirmed by Southern blot as described (6).
Founders and transgenic progeny were backcrossed to (CBA x C57BL/6)F1 mice (Harlan Olac) with transgenic males bred preferentially. All husbandry procedures (39) were carried out in accordance with Home Office Guidelines. Genotyping was as described above and CAG repeat size was determined as previously published (40). Mice were culled by cervical dislocation and tissues were removed for analysis. Either the whole brain was snap-frozen in isopentane, or dissected brain and body regions were snap frozen in liquid nitrogen prior to storage at -80 o C.
RNA extraction and expression analysis
RNA preparation, northern blots and RT-PCR, were performed as previously described (6) except that primers 40080 and 40085 were used for RT-PCR. RNA for real-time quantitative PCR (RQ-PCR) was prepared from 30 mg cerebral cortex from animals at 2 months of age using the RNeasy kit (Qiagen). Reverse transcription of 1 µg of total RNA was as previously described (6) except the reverse transcriptase was from Invitrogen. The RT reaction was diluted 2.5 fold in nuclease free water (Sigma) and 5 µl was used in a 25 µl reaction containing Taqman master mix (ABI), 300 nM primers and 200 nM probe using the ABI7700 Taqman. Primer sequences for amplification of the htt transgene were 40298 and 40299 and the probe was 40300; and for β-actin the primers were 40310 and 40311 and the probe was 40312 ( Table 3) . Estimation of mRNA copy number was determined in triplicate for each RNA sample through comparison to standard curves.
In situ hybridization analysis of transgene expression was performed as previously
described (41) with [ 35 S] end-labeled TG3 oligonucleotide probe targeted against a humanspecific intron of the human HD transgene sequence (Table 3) . Slides were exposed multiple times to Amersham β-max autoradiography film for 2, 7 and 14 days. In situ hybridization signal was analyzed by measuring film densities using a computer-based image analysis system (MI, Imaging Research) for striatum, superficial layers of frontal cortex, deep layers of frontal cortex, entorhinal cortex, dentate gyrus, CA1 and CA3 regions of hippocampus, thalamus, granule and molecular cell layers of the cerebellum. Average signal values (absolute optical density) were obtained for each region and correlation coefficients for all brain regions across all of the lines were calculated.
Protein extraction and western blotting
Cerebellar lysates were homogenized in sodium phosphate buffer (20mM NaPO 4 pH 7.4; 1% SDS) with 'Complete' protease inhibitors (GibcoBRL). Nuclear and cytoplasmic fractions were prepared from snap frozen whole brain as described (42) Film densities of bands were analyzed using a computer-based image-analysis system (MI, Imaging Research).
Phenotype analysis
An Ugo Basile 7650 Accelerating Rotarod for Mice (Linton Instruments) was used to test motor performance in a minimum of 10 transgenic mice and their littermate controls (age and sex-matched) as previously described (39) SHIRPA was performed on five transgenic and five wild type mice for each line studied at monthly intervals. The equipment and protocols necessary to conduct a SHIRPA screen are detailed at http://www.mgu.har.mrc.ac.uk/facilities/mutagenesis/mutabase/shirpa_summary.html.
Immunohistochemistry
Performed on 15 um coronal sections from isopentane frozen brains using the avidinbiotin system with 3, 3'-diaminobenzidine (DAB) as a chromogen and antibody dilutions were as previously described (45) except for FLAGBioM2 (1:1,000), mAb (Sigma).
Ultrastructural analysis and electron microscopic immunohistochemistry
Tissue perfusion, immunogold labeling with EM48 and electron microscopy were as previously described (13).
Microarray Analyses
Total RNA was isolated from frozen cerebella by Trizol reagent ( Mice were assessed monthly using the primary screen of the SHIRPA protocol until 12 months of age. The age indicates the earliest age at which a phenotype could be detected. The R6/2 mice are included for comparison (m=male, f=female) Endpoint indicates the age at which mice were culled (according to Home Office Project license requirements). -no phenotype detected.
